肉毒毒素联合透皮东莨菪碱降低串联PSMA核素治疗中的唾液腺摄取
本研究探讨A型肉毒毒素(incobotulinumtoxinA)联合透皮东莨菪碱对接受[225Ac]Ac-和[177Lu]Lu-PSMA串联核素治疗患者唾液腺摄取的防护作用。14例患者中,联合方案使肉毒毒素注射侧腮腺平均摄取较未注射对侧降低约30%,下颌下腺降低约17%,最高300单位肉毒毒素安全,无患者因口干终止治疗,未观察到3级或4级毒性。
要点
- 肉毒毒素联合透皮东莨菪碱可降低PSMA核素治疗中唾液腺摄取约30%(腮腺)和17%(下颌下腺)。
- 最高300单位incobotulinumtoxinA分布于主要唾液腺安全,未出现3/4级毒性。
- 无患者因口干终止串联PSMA治疗,该策略有望改善患者生活质量。
核心结论
- 肉毒毒素联合透皮东莨菪碱是降低PSMA核素治疗中唾液腺摄取的有前景策略,尤其适用于α发射体核素。
研究设计与样本
- 本研究纳入14例接受[225Ac]Ac-和[177Lu]Lu-PSMA串联核素治疗的患者,平均年龄68.0±8.1岁。
- IncobotulinumtoxinA在超声引导下经皮注射至腮腺和下颌下腺,剂量递增至最高300单位,平均于计划串联PSMA核素治疗前24天给药。
- 透皮东莨菪碱从核素治疗前72小时应用至治疗后2小时。
- 通过治疗前PSMA PET/CT确认配体摄取,治疗后SPECT/CT测量唾液腺摄取,计算注射侧与未注射对侧腺体的比值并进行比较。
主要发现
- 联合incobotulinumtoxinA与透皮东莨菪碱后,肉毒毒素注射侧唾液腺PSMA放射性配体摄取低于未注射对侧腺体。
- 腮腺平均摄取较未注射对侧降低约30%,下颌下腺降低约17%。
- 平均累积给药活度为177Lu 5.05±1.09 GBq、225Ac 6.87±3.14 MBq。
- 最高300单位incobotulinumtoxinA分布于主要唾液腺安全,无患者因口干终止串联PSMA治疗,PSMA核素治疗期间未观察到3级或4级毒性。
关键数值与推荐
- IncobotulinumtoxinA经超声引导经皮注射至腮腺和下颌下腺,剂量递增至最高300单位,平均于串联PSMA核素治疗前24天给药。
- 透皮东莨菪碱从核素治疗前72小时应用至治疗后2小时。
- 腮腺摄取平均降低约30%,下颌下腺降低约17%(注射侧与未注射对侧比较)。
临床怎么用
- 对接受[225Ac]Ac-和[177Lu]Lu-PSMA串联核素治疗的患者,可考虑在治疗前约24天经超声引导行incobotulinumtoxinA唾液腺注射,并联合透皮东莨菪碱(治疗前72小时至治疗后2小时)以降低唾液腺摄取。
- 该防护策略安全性良好,最高300单位incobotulinumtoxinA未出现3/4级毒性,无患者因口干终止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) has shown remarkable efficacy in advanced metastatic castration-resistant prostate cancer. However, salivary gland toxicity is a major dose-limiting adverse effect, particularly with α-emitting radionuclides such as 225Ac. Although tandem therapy with combined [225Ac]Ac- and [177Lu]Lu-labeled PSMA-targeted RPT in a single low-activity cycle may address certain challenges, effective salivary gland protection remains crucial. In this study, we explored the use of botulinum toxin (BTX) type A (incobotulinumtoxinA) plus transdermal scopolamine as a protective strategy to mitigate salivary gland uptake of PSMA radioligands. Methods: IncobotulinumtoxinA was injected percutaneously, with increasing dosages of up to 300 units distributed into the parotid and submandibular glands under ultrasound guidance, a mean of 24 d before scheduled tandem PSMA RPT. Transdermal scopolamine was applied from 72 h before RPT until 2 h after RPT. Molecular imaging was conducted as per PSMA RPT protocol, with pretreatment PSMA PET/CT to confirm ligand uptake and follow-up PET/CT for restaging. SPECT/CT was conducted as imaging after RPT. PET SUVmean or SPECT counts were measured, and ratios of injected-to-noninjected contralateral glands were calculated and compared before and after BTX. Results: Fourteen patients (mean age, 68.0 ± 8.1 y) were included; 1 patient received 2 injections before his treatment, and another underwent 2 tandem RPT cycles, with BTX administered before each cycle. Mean cumulative administered activity was 5.05 ± 1.09 GBq for 177Lu and 6.87 ± 3.14 MBq for 225Ac. Combination therapy with incobotulinumtoxinA plus transdermal scopolamine was associated with lower PSMA radioligand uptake in BTX-treated salivary glands relative to untreated contralateral glands, with mean reductions of approximately 30% in parotid glands and 17% in submandibular glands compared with untreated glands. Up to 300 units of incobotulinumtoxinA distributed among the major salivary glands was safe. No patient discontinued tandem PSMA therapy because of xerostomia, and no grade 3 or 4 toxicities were observed during PSMA RPT. Conclusion: BTX plus transdermal scopolamine is a promising strategy to reduce salivary gland uptake during PSMA RPT. This approach enhances patient quality of life after PSMA radiopharmaceutical therapy, particularly with α-emitting radionuclides, while preserving its excellent therapeutic efficacy.
引用
- Mueller J, Zhao T, Jakobsson V, et al. Botulinum Toxin Plus Transdermal Scopolamine Reduces Salivary Gland Uptake in Patients Undergoing Tandem Radiopharmaceutical Therapy with [225Ac]Ac- and [177Lu]Lu-PSMA Radioligands. J Nucl Med. 2026. PMID: 42957205. doi:10.2967/jnumed.125.271922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。